Fact checked by Nick Blackmer Zunveyl (benzgalantamine)—a better-tolerated version of the Alzheimer’s drug Razadyne ...

The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...

Independence Blue Cross has instituted an 18-month benefit exclusion on certain drugs that receive accelerated approval from ...

On Monday, the FDA accepted Eisai Co., Ltd. (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Biologics License Application (BLA) ...

To date, Leqembi has been approved in the US, Japan, China, South Korea, Hong Kong, Israel, UAE, GB, Mexico, and Macau, and ...

The agreement with China Medical System Holdings Limited is for the development, manufacturing, and commercialization of ...

which is currently under FDA review. Approval for a monthly IV dose of Leqembi is also being sought. The Alzheimer’s Drug Discovery Foundation (ADDF) also welcomed the approval, saying it would ...

While the Alzheimer’s market is projected to experience strong growth throughout the forecast period across the 8MM, unmet ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...

Anavex's financial health is stable with cash runway into 2028, but rising expenses are expected. Click here to find out why ...

As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...